“…The association between vaccination and development of CSVV has been reported in literature with various vaccines, namely: influenza, hepatitis A, hepatitis B, bacillus Calmette-Guérin, anthrax, human papillomavirus, measles-mumps-rubella, and pneumococcal vaccines. 25 Among the available COVID-19 vaccines, LCV has been reported with messenger RNA-based vaccines (BNT162b2 [Pfizer-BioNTech] 6,8-12 and mRNA-1273 [Moderna], 6,7 adenoviral vectorbased vaccines [ChAdOx1 nCoV-19; Oxford-AstraZeneca]), [13][14][15][16][17][18][19] and inactivated vaccines (Covaxin, 20,21 Sinovac, 22,23 and unspecified inactivated vaccines 24 ) (Table 1). Most of the reported vaccine-related cutaneous LCV were limited to the skin and only few were associated with systemic involvement.…”